For acute musculoskeletal pain, Toradol (ketorolac) can be added to an IV protocol when clinically appropriate
With the rise of interest in IV Therapy, individuals often search for IV Therapy near me to find reliable providers
[4] Users should discontinue use if they experience any signs of allergic reactions, such as redness, hives, or itchiness
[DOI] [PMC free article] [PubMed] [Google Scholar] 28.Tomsi K., Domanjko Petri A., Nemec A., Pirman T., Rezar V., Selikar A., Vovk T., Nemec Svete A
17 , e3000323 (2019)
A 2020 review on the safety of BPC-157 in preclinical (animal) studies states that the peptide did not show any test-related effects in the single-dose toxicity study and that it was well tolerated in repeat-dose evaluations.16 Other animal studies and reviews mention that BPC-157 has no reported toxicity or that it was without a lethal dose in toxicology studies.14 17 Even the authors of a small human study on BPC-157 for interstitial cystitis note that no one dropped out of the study, and no adverse events were reported.18 We want to highlight that most of the relevant studies have been conducted on animals, and more human research is needed
